Andreas Plückthun

24 April – Andreas Plückthun – between basic research and biotech entrepreneurship

In Entrepreneurially driven academics are thinly spread in Europe

One would be pressed very hard to find even more than a handful that have started not just one but three successful biotech companies. One of them is Andreas Plückthun, Professor at the Department of Biochemistry at the University of Zurich as well as co-founder of Morphosys, Molecular Partners and G7 Therapeutics (now Heptares-Zurich). We are delighted to have Andreas Plückthun talking about his path between basic science and entrepreneurship. He recounts how he successfully co-founded several biotech companies and how the ecosystem for startups has evolved in the last 20 years.

Please join us at this event. April 24th 2018, 19:00 to 20:00, at Halle 7, Gundeldingerfeld, Dornacherstrasse 192, in Basel.


18:45 Door opening
19:00 Introduction
19:05 Andreas Plückthun
19:35 Q&A
20:00 Apero

Participation to the event is free of charge; however, your registration until April 23th is mandatory. To join us please register here.

In a recent interview, Andreas Plückthun said: “I enjoy thinking about seemingly unsolvable problems”. Click here to read more.

Andreas Plückthun

Andreas Plückthun (*1956) is a biochemist whose research is focused on the field of protein engineering. He is Full Professor at the Department of Biochemistry at the University of Zurich, where he was appointed in 1993. Plückthun received his PhD from UC San Diego (1982). He was Postdoctoral Fellow at Harvard University (1982-85) before becoming group leader at the Max-Planck-Institute of Biochemistry, Germany (1985-1993). In 1992, he was elected to the European Molecular Biology Organization (EMBO), and named a member of the German National Academy of Science (Leopoldina) in 2003. He is the recipient of numerous international prizes, having been named “a pioneer of protein engineering”. In addition, Plückthun is cofounder of three biotechnology companies: Morphosys AG (Martinsried, Germany), Molecular Partners AG (Zürich-Schlieren, Switzerland) and G7 Therapeutics (now Heptares-Zurich, Zürich-Schlieren, Switzerland).